Skip to content

Trial · Interventional

CompletedPhase 3Registry data

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

NCTNCT07820111 (opens ClinicalTrials.gov in a new tab)Other idKACST,KSA:H-11-N-136
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 3
Enrollment
159 participants (actual)
Sponsor
Zagazig University · Other gov
Design
Randomized · Open label (no masking)
Countries
1 country

Saudi Arabia

Start
18 Oct 2025
Primary completion
17 Mar 2026
Completion
17 Mar 2026
First posted
15 Sept 2026
Last update posted
15 Sept 2026
Conditions
Obese Diabetics · Obese Non Diabetic

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202520262027
  1. Ph 3

    Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

    NCT07820111

    18 Oct 2025 to 17 Mar 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA Dulaglutide, Semaglutide, Tirazepetide among diabetic and non -diabetic participant as the well-known fact that they don't have only weight recuing effect but also many different effects on metabolic process including insulin sensitivity, lipid profile and NASH. Materials and Methods: This is a randomized controlled study involving a total of 159 participants, divided into 75 non-diabetic and 84 diabetic obese individuals. Participants were assigned to three drug groups, each receiving a once-weekly dose of Dulaglutide, Semaglutide, or Tirzepatide for a period of 24 weeks. Each drug group consisted of 53 individuals, subdivided into 25 non-diabetic and 28 diabetic participants. Measurements were taken at three time points: pretreatment, 3 months post-treatment, and 6 months post-treatment. Each participant underwent a complete physical exam, and data was collected on weight, BMI, age, and sex and Laboratory tests. , also repeated measurements were taken at 3 and 6 months post-treatment. on metabolic processes, weight reduction, and insulin sensitivity, particularly in diabetic individuals, as well as effects on lipid profiles and liver enzymes, weight reduction, BMI, HbA1c, TYG-index, triglycerides, and HDL-C levels. total cholesterol (Tc) and liver enzymes. Data were collected, and statistical analyses were conducted afterward.

Interventions

  • Dulaglutide 1.5 MG/MLDrug
  • Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solutionDrug
  • Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physicianDrug
  • Dulaglutide 0.75mg subcutaneous injectionDrug
  • Semaglutide 1.0 mgDrug
  • Tirzepatide (Flexible titration)Drug

Arms6

  • Active comparator

    obese , non diabetic ,recieve dulaglutide

    GLP1-RA

  • Active comparator

    obese , non diabetic ,receive SEMAGLUTIDE

    GLP1-RA

  • Active comparator

    obese , non diabetic ,receive TIRAZEPETIDE

    GLP1-RA

  • Active comparator

    obese , diabetic ,recieve dulaglutide

    GLP1-RA

  • Active comparator

    obese , diabetic ,receive SEMAGLUTIDE

    GLP1-RA

  • Active comparator

    obese , diabetic ,receive TIRAZEPETIDE

    GLP1-RA

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. change in body weight at 3 and 6 months

    Time frame · 6-MONTH STUDY PERIOD

    Registry description

    Change from baseline in body weight (kg) at 3 and 6 months among diabetic and non-diabetic participants receiving weekly GLP-1 receptor agonists.

Secondary outcomes(8)

  1. Change in Body Mass Index (BMI)

    Time frame · 3 months, and 6 months

    Registry description

    Change in BMI from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: kg/m²

  2. Change in Glycated Hemoglobin (HbA1c)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in HbA1c from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: %

  3. Change in Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in LDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL

  4. Change in Triglycerides

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in serum triglyceride concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL

  5. Change in Alanine Aminotransferase (ALT)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in serum ALT concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: U/L

  6. Change in Aspartate Aminotransferase (AST)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in serum AST concentration from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: U/L

  7. Change in High-Density Lipoprotein Cholesterol (HDL-C)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in HDL-C from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL

  8. Change in Total Cholesterol (TC)

    Time frame · Baseline, 3 months, and 6 months

    Registry description

    Change in TC from baseline to 3 months and 6 months among participants receiving GLP-1 receptor agonists, analyzed separately in diabetic and non-diabetic participants. Unit of Measure: mg/dL

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * overweight or obese, diabetic, or non-diabetic Exclusion Criteria: * Patients who will refuse to be enrolled in the study or refuse to sign the consent

PepBank is a research reference. Talk to a doctor before you use any peptide.